YOU ARE UNIQUE!

Your diagnosis should be as well!

Your Access to personalized diagnostics

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla suscipit finibus neque, id porttitor velit commodo ornare. Mauris volutpat dignissim […]

Mehr erfahren

GeneSurge is your access to individualized diagnostics

Even though we classify tumors according to their place of origin and appearance, each one remains somewhat different at the molecular level. And that is exactly what makes each cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specific to the individual patient.

With 3 Tests to reach your individual results

TheraTissue

Every cancer is as individual as the patient.

X

TheraTisue

Every cancer is as individual as the patient. For this purpose, TheraTissue was developed, which combines the mutation study of all coding genes (Whole Exome) with the information of the expressed and thus active genes (Full Transcriptome). The resulting data are then individually tailored to the patient and analyzed in a personalized network analysis on their importance in terms of treatment options.

This will make it possible to make more specific statements about the response of therapeutics. A special feature is that also drugs used for other cancers or completely different diseases (such as diabetes, Arthroses or transplant rejection) and complementary products are being examined for their potential effect on the specific cancer.

X

AllBlood

Only for those who get cancer and systemic diseases recognized early treatment can be started promptly and effectively.

X

AllBlood

Only for those who get cancer and systemic diseases recognized early treatment can be started promptly and effectively. AllBlood is a purpose-built analysis that combines 12 single, large-scale tests to diagnose the presence of a tumor in the blood. This brings together the information from all coding genes (Whole Exome) with the expressed and thus active genes (Full Transcriptome) and other levels of investigation – for example miRNA but also epigenetic changes (i.e. methylation and hydroxy-methylation). The basis of this multidimensional network analysis and the data set generated with it then give indications as to whether a tumor is present, where it originated, and in many cases how it can be treated. The test is similar to a whole-body examination in the blood.

X

TheraBlood

Once a tumor grows and spreads, it releases components of itself to the blood.

X

TheraBlood

Once a tumor grows and spreads, it releases components of itself to the blood. These components are not exclusively circulating tumor cells – which for the most part do not lead to the formation of metastases – but also cell components.

Two components are of particular interest for the analysis: on the one hand the cell-free DNA, which is released in the cell death of individual cancer cells and on the other the cell-free RNA (due to small constrictions of tumor cells, so-called vesicles but also exosomes). TheraBlood examines all the variabilities in the blood, which can be a certain statement about the mutation of the different genes (Whole Exome) and their expression at the RNA level (Full Transcriptome) can be made.

Thus, a data analysis as in TheraTissue is possible, but also an additional identification of individual biomarkers of the patient for future therapy monitoring.

X

GeneSurge aims to allow each patient to be treated as best as possible

GeneSurge has a clear goal: to provide sufficient information so that each patient can receive the drugs that work most effectively against the specific tumor. In order to achieve this, several factors are taken into account in the analysis, whereby conclusions can be made that a tumor responds - due to its heterogeneity - partly even with certain areas sensitive to a treatment. If the blood is examined with highly sensitive methods, then the individual tumor components can be made measurable, which leads to an overall picture of the tumor and it is possible without any access to the tissue. This is called a liquid biopsy.

X

The Liquid Biopsy

Although we classify tumors according to their place of origin – for example, pancreatic cancer, breast cancer, colon cancer, ovarian cancer, lung cancer, gastric cancer or prostate cancer – as well as their appearance (e.g., small cell lung cancer), each one remains somewhat different at the molecular level. And that is exactly what makes cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specifically tailored to each patient.

The treatment of most patients is based on certain guidelines for standard medical treatment. This is understandable insofar as that hundreds and thousands of subjects for therapy success or failure were examined. A not insignificant percentage shows a correspondingly good response to the treatment, otherwise the doctor would not initiate this treatment. The reality shows, however, that unfortunately the majority of patients cannot achieve a positive result. And that’s exactly why it is essential to find out who benefits from which therapy and to adjust the treatment accordingly in a timely manner in order to provide the best possible therapeutic care. That’s exactly what GeneSurge aims to do: provide enough information to help every patient get the drugs that are most effective against his tumor.

To achieve this, several factors are taken into account in the analysis. Any solid tumor (other than leukemia, except for testing) is characterized by heterogeneity, which means that the individual areas may well be different. On the one hand, they carry different mutations and, on the other, some other genes are active. Therefore, among other things, a partial response to a therapy comes about because only certain areas of the tumor are sensitive to the treatment. After all, this is the reason why GeneSurge is analyzed in a particularly profound way, only in this way can those differences be revealed. In another test, which is also offered, you also take advantage of the biology of the tumor.

To a certain extent, however, the cells sometimes give up their DNA (packaged in small packets to express it figuratively) or their RNA (contained in constrictions of tumor cells, so-called vesicles) into the blood. If one examines the blood now with highly sensitive methods, then these tumor components can be made measurable, which leads to an overall picture of the tumor and without having had access to the tissue. This is called a liquid biopsy.

X

How is the test working?

Each person is individual and therefore all results are compared with the personal genetic background, so that the changes within the tumor can be better determined. For this purpose, the test isolates the DNA and RNA from all samples, which are sequenced (NGS) in the subsequent test procedure.

X

How is the test working?

Each person is individual and therefore all results are compared with the personal genetic background, so that the changes in the tumor can be better determined. Therefore, the “normal” DNA from the blood or in a non-tissue assay, the RNA is also analyzed. In the test, the DNA or RNA are isolated for all samples. As a result of this purification, the molecular information at the level of the nucleic acid (DNA and RNA are core representatives) is extracted from the sample and enriched by means of specific chemistry. In the case of DNA, all coding regions of the genome, i.e. the entire exome, are specifically extracted, since this is responsible for the production of all endogenous proteins.

Of these genes, humans have, depending on how one calculates this, at least 25,000. In RNA, for testing frequent varieties, which receive no specific information for a therapy, so rRNA and the globulins in the blood are removed. In the further procedure, the ends of all fragments, the DNA and the RNA have been broken into small pieces at this time, provided with analysis-specific essays. These essays, in turn, are necessary for the subsequent analysis. For better identification, so-called bar codes are added to make each sample unique. We now speak of a “library” for sequencing. This will be investigated by means of Next Generation Sequencing (NGS). Here, several million individual values ​​are collected in parallel, with the RNA, for example, 50 million so-called clusters or single sequences are recorded. In contrast to classical sequencing according to the so-called Sanger method, it is possible to obtain results within days and weeks, e.g. needed several years for the human genome project.

The sequencer measures the signals for each individual fragment as light in certain colors and translates this into the building blocks of the RNA or DNA. The result is a huge text file that lists all sequences found. This file (FASTQ) is now matched with known references of the human genome and the individual genetic background by comparing the patient’s normal genome to the tumor sample. DNA from the tumor produces a list of mutations that are specific to cancer, called somatic mutations. In the case of RNA, the number of specific copies (transcripts) is measured and thus the activity or the so-called expression is shown. These results will be reviewed in detail.

X
CONTACT US
01

Individual patient

Our test is characterized by a cycle in which the patient always stands in the center and whose start and end point he is.

[ Show less ]
02

Blood collection

Blood is drawn with various blood collection tubes that specifically stabilize certain components. This allows a differentiated evaluation.
+ Tumor tissue: Already taken tumor material (FFPE, formalin fixed, paraffin embedded tissue; pathology sample) is used for testing. The extracted blood is used for the adjustment.

[ Show less ]
03

Shipping to the laboratory

The collected patient samples are sent to the lab.

[ Show less ]
04

Isolation of RNA and DNA

In order to obtain a correspondingly differentiated result, RNA and DNA are isolated from all samples.

[ Show less ]
05

Analysis via sequencing

Now it comes to the testing of the samples. All tests are standardized to ensure the highest quality. The analysis is carried out by means of sequencing (Next Generation Sequencing, NGS). In DNA sequencing, all coding gene regions (whole exomes) are tested in detail, generating approximately 50 million individual values for the RNA. This allows a data analysis that specifically addresses the patient.

[ Show less ]
06

Bioinformatics
data analysis and finding of relevant information

The data analysis then leads to the fusion of all data (DNA, RNA) with a comparison of the patient groups with known therapy output from the databases. This network analysis provides new facts and creates the unique opportunity to find new ways of therapy. For this purpose, all approved drugs are virtually tested for a possible effect.

[ Show less ]
07

Filtering of data and creation of a signature for targeted therapy

The specific and therapy-relevant data are summarized. In addition, information about the immune status (tumor and blood) is generated. Individual biomarkers in the blood that enable therapy monitoring are identified and an understanding of the genetic background is developed to estimate possible side effects.

[ Show less ]
08

Sending of the report

The collected information is sent to the doctor and the patient and this allows the physician to choose the best possible treatment for the individual patient.

[ Show less ]
09

Individual patient

The patient now has an individual information and data overview in his hands, which makes it possible to start immediately with a tailor-made treatment by the attending physician.

[ Show less ]

Your get tailored therapy recommendation information

The result of the tests includes a listing of possible therapeutics as well as the sensitivity of the tumor. In addition, a targeted therapy monitoring is possible after this first test. For this purpose, individual and tailored to the patient tumor markers are first identified from the data. These can then be checked in almost real time during the course of therapy using other technologies (quantitative polymerase chain reaction, qPCR). In this way, the treatment can be individually adapted months before the results of imaging procedures.
X

High sensitivity testing for your individual results

In the first analysis of a new patient, two tests are carried out: that of the tumor (one blood tube / EDTA is used to compare the genetic background) and that of the blood (also one EDTA tube, plus three other types of blood sampling). The isolation of the RNA or DNA is specific to this type of sample. Subsequent to the nucleic acid recovery, the samples are transformed into a standardized method. The primary application of the test is for cancers, i.e. the detection of solid tumors. Nevertheless, the blood test is also suitable for the detection of other diseases, such as neurological, auto-immune and systemic diseases. On request, possible objectives can be discussed individually here. The huge amounts of data will be compared to database entries.

It is examined whether individual changes (markers) are associated with therapy behaviors, whether certain processes and signaling pathways in the tumor cells are changed (Pathway Analysis) and how the individual patient behaves in comparison to measured patient groups with a known course of therapy (cohort analysis). However, as this only shows a small spectrum, each patient also performs a network analysis to find out how the individual changes interact with each other. Again, these interactions are compared with all known data sets and additionally checked with our own algorithms for their therapeutic importance.

All analyzes are ultimately fused, resulting in a simple listing of drugs and therapeutics with a likelihood calculation of their impact on the individual patient. Not only are drugs targeted for the specific cancer, but also other tumor types, completely different areas (such as osteoarthritis or diabetes) and complementary medicine.

X
WE SUPPORT YOU

Tailored Therapy by us, with treatment by your physician

The commissioning of a GeneSurge always takes place in the first step via a patient consent. You or your doctor will be sent sample tubes for the blood test. In the case of tumor analysis, the doctor instructs a pathologist, who stores your tumor tissue, to send a certain amount of this sample to our laboratory - this is a very small amount (15 so-called blanks). The analysis time after receipt of the sample in the laboratory is about one month, billing takes place immediately after receiving the sample. Please remember that it is important that you have discussed everything with your attending physician to ensure the best possible use of each patient's tests. The results are communicated to both the doctor and you as a patient.

The tests will provide you with valuable information regarding a possible response of a tumor to different drugs. Nevertheless – understandably – the therapy is in the hands of the attending physician. For this reason, it is particularly important to communicate the data obtained from the test as early as possible.

In order for the results to be transmitted smoothly and promptly, please notify your treating physician with the patient’s consent. The findings sent to him will specifically mention therapeutics that your doctor considers appropriate. In addition, the findings will be sent directly to him. You have further questions about the process in this regard?

Then please contact GeneSurge’s info mail.

ROBERT LOEWE

Robert Loewe has been working in the field of diagnostics since 2000, with parts of his development findings currently use in blood and tissue analysis. The greatest ambition of his work revolves around the early detection of diseases such as cancer, the personalized diagnostics and tailor-made forms of therapy and thus the chance of each individual patient to improve.


X

Robert Loewe

Robert Loewe has been working in the field diagnostics since 2000 and has had the opportunity to participate in a variety of projects. His first work in this regard was the analysis of tumors at the cellular level for chemosensitivity testing at CellControl. After intermediate steps in the field of protein analysis and enzyme research in cancer, Robert Loewe worked for Roche Pharma and Roche Diagnostics in the field of oncology. Among other things, he has worked on cancer screening as well as therapy prediction of own products for Roche.

He was also involved in various projects at other pharmaceutical and diagnostics companies, such as Novartis and other major corporations. Some of his developments are now used in blood and tissue analysis as well as therapy classification of patients. The ultimate goal of Robert Loewe is to make the most up-to-date research and the latest methods available to patients in order to give each one their best possible treatment by the doctor. His ambition is to personalize the diagnostics so that each treatment can be tailored to the success of the therapy.

Robert Loewe´s concern is the early detection of diseases like cancer and in this way the improvement of the prognosis of each individual patient.

X

Publications

Vita

Publikationen (und ich hab bestimmt was vergessen, ich publiziere eigentlich nicht; 2011 war nen Buchkapitel und kompletter Überblick zu einer Unterart von Bioinformatik und 2013 ist die erste Veröffentlichung die NGS und qPCR für Krebsdiagnostik zur Idee der Therapieanpassung verwendet hat):

Kretschmer A., Milo P.-S. , Löwe R., Stief C. G. , Tilki D. Die Genexpressionsanalyse von AMACR in Vollblut als potenzieller diagnostischer Marker des Prostatakarzinoms. 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie 15.–17. Mai 2014

Loewe RP. Combinational usage of next generation sequencing and qPCR for the analysis of tumor samples. Methods. 2013; 59:126-131.

Paulis Y, Dinnes D, Soetekouw P, Nelson PJ, Burdach S., Loewe RP, Tjan-Heijnen V, von Luettichau I., Griffioen AW. Imatinib reduces the vasculogenic potential of plastic tumor cells; Current Angiogenesis. 2012; 1: 64-71.

von Toerne C, Bedke J, Safi S, Porubsky S, Gretz N, Loewe R, Nelson PJ, Gröne HJ. Modulation of Wnt and Hedgehog signaling pathways is linked to retinoic acid-induced amelioration of chronic allograft dysfunction. Am J Transplant. 2012 Jan;12(1):55-68. 

Loewe RP, Nelson PJ. Microarray bioinformatics. Methods Mol Biol. 2011;671:295-320.

Dehmel S, Wang S, Schmidt C, Kiss E, Loewe RP, Chilla S, Schlöndorff D, Gröne HJ, Luckow B. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol. 2010 Jan;40(1):267-78.

Luckow B, Hänggli A, Maier H, Chilla S, Loewe RP, Dehmel S, Schlöndorff D, Loetscher P, Zerwes HG, Müller M. Microinjection of Cre recombinase protein into zygotes enables specific deletion of two eukaryotic selection cassettes and enhances the expression of a DsRed2 reporter gene in Ccr2/Ccr5 double-deficient mice. Genesis. 2009 Aug;47(8):545-58.

Zerwes HG, Li J, Kovarik J, Streiff M, Hofmann M, Roth L, Luyten M, Pally C, Loewe RP, Wieczorek G, Bänteli R, Thoma G, Luckow B. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant. 2008 Aug;8(8):1604-13. 


Harzmann R, Esser N, Loewe R, Roberts J, Leenders F, Seifert W, Unger C, Drevs J. Glutaminase (PEG-PGA) increases antitumoral efficacy of cytotoxic agents J Clin Oncol. 2004; 22:3183

Loewe R. Talk and Poster (together with HR Tinneberg) at the 6th Nottingham International Breast Cancer Conference Sep. 2001, Nottingham: ChemoSelect, a chemosensitivity test to predict the response of tumor cells to certain cytostatic agents.

Vita

Robert Loewe has been working in the field diagnostics since 2000 and has had the opportunity to participate in a variety of projects. His first work in this regard was the analysis of tumors at the cellular level for chemosensitivity testing at CellControl. After intermediate steps in the field of protein analysis and enzyme research in cancer, Robert Loewe worked for Roche Pharma and Roche Diagnostics in the field of oncology.

Among other things, he has worked on cancer screening as well as therapy prediction of own products for Roche. He was also involved in various projects at other pharmaceutical and diagnostics companies, such as Novartis and other major corporations. Some of his developments are now used in blood and tissue analysis as well as therapy classification of patients. The ultimate goal of Robert Loewe is to make the most up-to-date research and the latest methods available to patients in order to give each one their best possible treatment by the doctor.

His ambition is to personalize the diagnostics so that each treatment can be tailored to the success of the therapy. Robert Loewe´s concern is the early detection of diseases like cancer and in this way the improvement of the prognosis of each individual patient.

CONTACT US

Name
E-Mail
Message